MNMD Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Mind Medicine's net margin of --. Mind Medicine's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Mind Medicine has a consensus price target of $24.50, signalling upside risk potential of 185.55%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.1071 which suggests that it could grow by 245.76%. Given that Perspective Therapeutics has higher upside potential than Mind Medicine, analysts believe Perspective Therapeutics is more attractive than Mind Medicine.

Mind Medicine has a beta of 2.803, which suggesting that the stock is 180.283% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.701%.

Mind Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mind Medicine pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Mind Medicine quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Mind Medicine's net income of -$23.3M is lower than Perspective Therapeutics's net income of -$18.2M. Notably, Mind Medicine's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mind Medicine is -- versus 28.76x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Mind Medicine's net margin of 12.06%. Mind Medicine's return on equity of -- beat Electromed's return on equity of 16.57%.

Mind Medicine has a consensus price target of $24.50, signalling upside risk potential of 185.55%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 81.87%. Given that Mind Medicine has higher upside potential than Electromed, analysts believe Mind Medicine is more attractive than Electromed.

Mind Medicine has a beta of 2.803, which suggesting that the stock is 180.283% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Mind Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mind Medicine pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Mind Medicine quarterly revenues are --, which are smaller than Electromed quarterly revenues of $15.7M. Mind Medicine's net income of -$23.3M is lower than Electromed's net income of $1.9M. Notably, Mind Medicine's price-to-earnings ratio is -- while Electromed's PE ratio is 23.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mind Medicine is -- versus 2.69x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -- compared to Mind Medicine's net margin of -2201.34%. Mind Medicine's return on equity of -- beat VolitionRX's return on equity of --.

Mind Medicine has a consensus price target of $24.50, signalling upside risk potential of 185.55%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 320%. Given that VolitionRX has higher upside potential than Mind Medicine, analysts believe VolitionRX is more attractive than Mind Medicine.

Mind Medicine has a beta of 2.803, which suggesting that the stock is 180.283% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Mind Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mind Medicine pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Mind Medicine quarterly revenues are --, which are smaller than VolitionRX quarterly revenues of $246.4K. Mind Medicine's net income of -$23.3M is lower than VolitionRX's net income of -$5.4M. Notably, Mind Medicine's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mind Medicine is -- versus 48.25x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Mind Medicine's net margin of 0.18%. Mind Medicine's return on equity of -- beat Xtant Medical Holdings's return on equity of -26.62%.

Mind Medicine has a consensus price target of $24.50, signalling upside risk potential of 185.55%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 201.72%. Given that Xtant Medical Holdings has higher upside potential than Mind Medicine, analysts believe Xtant Medical Holdings is more attractive than Mind Medicine.

Mind Medicine has a beta of 2.803, which suggesting that the stock is 180.283% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Mind Medicine has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mind Medicine pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Mind Medicine quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Mind Medicine's net income of -$23.3M is lower than Xtant Medical Holdings's net income of $58K. Notably, Mind Medicine's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mind Medicine is -- versus 0.65x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.